

FOREUM Platinum Recognition awarded for the third time

3 June 2020, Kilchberg, Switzerland – FOREUM, the Foundation for Research in Rheumatology, has again awarded Platinum Recognition. Today AbbVie, Galapagos, Eli Lilly, Novartis Pharma AG, Pfizer, and UCB received FOREUM’s recognition during the virtual EULAR Opening Plenary Session.

FOREUM is delighted and proud to announce that in 2020 six donors can be awarded with Platinum Recognition. FOREUM President Prof. Gerd Burmester is very pleased and states that “FOREUM is very grateful for the support of six companies at the platinum donor level. Their ongoing commitment for research in rheumatology, in some cases over many years, shows us that the foundation is developing in the right direction”.

Representative of **Pfizer**, Dr. Isabelle Logeart, Global Medical Affairs Asset Lead Inflammation & Immunology, commented, “Pfizer is committed to advancing research and transforming the lives of patients with inflammatory conditions. To receive the FOREUM Platinum Recognition is an honour – and highly appreciated”.

Receiving the recognition for the second time, Dr. ‘Matladi Ndlovu, Global Lead Innovative Precision Medicine Partnerships at **UCB** said “UCB is proud to receive FOREUM Platinum Recognition 2020 for contributing towards research and innovation in RMD” and Dr. Inmaculada de La Torre, International Therapy Area Medical Leader Rheumatology at **Eli Lilly** states that “Eli Lilly is driven to change what’s possible for people living with immune mediated diseases and therefore invests in leading-edge clinical approaches across the immunology portfolio in hopes of transforming the autoimmune disease treatment experience and improving patients quality of life”.

Dr. Thijs Hendriks, Global Medical Affairs Lead Inflammation at **Galapagos**, first time recipient of the Platinum Recognition said, “Galapagos is committed to beating inflammatory diseases. We are honoured to cooperate with FOREUM in its scientific endeavours; knowing that we can support the wellbeing of people around the world gives us the determination we need to continue our innovative research”.

Having been loyal donors to the foundation from its very beginning, FOREUM also recognizes **Novartis Pharma AG** and **AbbVie** for their scientific partnership supporting shared research objectives in rheumatic and musculoskeletal disease transforming clinical practice to improve patients’ quality of life.

FOREUM Foundation for Research in Rheumatology is devoted to promote research in rheumatic and musculoskeletal diseases (RMDs) as an independent research funding body in rheumatology research. To achieve this goal, FOREUM seeks to raise funds from various donors; through donations, basic and applied research of the highest quality can be supported to reduce the burden of disease for people with RMDs.

About FOREUM

FOREUM Foundation for Research in Rheumatology is promoting health in individuals with rheumatic and musculoskeletal diseases through effective research. FOREUM is an independent fundraising institution for research funding based in Switzerland. FOREUM is recognized by the Swiss authorities according to Swiss law and foundation regulations as a not-for-profit organisation. FOREUM is supported by EULAR, the European League Against Rheumatism.

Contact

Caroline Desiderio, Foundation Manager, caroline.desiderio@foreum.org, Tel. +41 78 895 08 00.